Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe United States | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Novartis Foundation | en
  • Sandoz | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe United States

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Novartis in the US
        • Company at a Glance
        • By the Numbers
        • Diversity and Inclusion
        • Pay Transparency-EPIC
        • Our Code of Ethics
      • Strategy
      • Diversity and Inclusion
        • Ensuring Equity
        • The Spirit of Inclusivity
        • Toward a better society
        • Parental Leave
        • Standing for Racial Equity and Justice as One Novartis
        • Novartis US EEO / D&I Report 2021
        • Supplier Diversity
      • People and Culture
      • Products
      • Country Leadership Team
      • External Funding
      • Contact Us
      About
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Patient Assistance
      • Diseases
      • Participating in Clinical Trials
      • Patient Perspectives
      • Adverse Event Reporting
      • The STEP Program
        • Sickle Cell Disease (SCD)
        • Program Overview
        • Multiple Sclerosis (MS)
        • Cancer
        • Application for Funding to Help Address Health Disparities
        • Health Disparities
      Patients and Caregivers
    • Healthcare Professionals
      • Novartis Pipeline
      • Novartis Clinical Trials
      • Adverse Event Reporting
      Healthcare Professionals
    • ESG
      • Ethical Behavior
        • Code of Ethics
        • SpeakUp
        • PhRMA Code on Interactions with Healthcare Professionals
        • Business Principles
      • Ethics, Risk and Compliance
        • Compliance Program
        • State Laws
        • Corporate Integrity Agreement
        • Payments to HCPs & HCOs
        • Enhanced Verification Request
      • Corporate Responsibility
        • Population Health
        • Novartis in Society US Reports
        • Novartis US Foundation
        • Environmental Sustainability
        • People and Communities
      • Beacon of Hope
        • Beacon of Hope: Measurable solutions for health equity
      ESG
    • News
      • News Archive
      • Statements
      • Stories
      • Contacts
      News
    • Careers
      • Career Search
      • Meet the Teams
      • Career Programs
      • Personal Growth
      • Early Talent
      • How We Work
      • Employee Benefits
      • Diversity and Inclusion
      • Awards & Recognition
      Careers
    • Coronavirus
      Coronavirus
    Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Releases
  • Stories
  • Featured News
  • Statements
icon
News Archive Navigation Language
  • English
  • French
  • German

November 2021

  • Media ReleaseNov 01, 2021
    FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
    Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine…

October 2021

  • Media ReleaseOct 14, 2021
    Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosis
    ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
  • Media ReleaseOct 13, 2021
    Novartis announces FDA and EMA filing acceptances of BEOVU® for patients with diabetic macular edema
    Regulatory decisions for BEOVU® (brolucizumab-dbll) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…

September 2021

  • Media ReleaseSep 19, 2021
    Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
    - With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
  • Media ReleaseSep 19, 2021
    Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
    With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
  • Media ReleaseSep 17, 2021
    Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
    PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks…
  • Media ReleaseSep 17, 2021
    Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
    PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24…

August 2021

  • Media ReleaseAug 31, 2021
    Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)
    PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disordersNew initiative…
  • Media ReleaseAug 31, 2021
    Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)
    PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disorders New…
  • Media ReleaseAug 17, 2021
    Novartis announces positive results from Phase III trials of BEOVU® in diabetic macular edema, including dosing intervals up to 16 weeks
    Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…

July 2021

  • Featured NewsJul 20, 2021
    Beacon of Hope: Addressing health disparities through holistic community-based collective action
  • Media ReleaseJul 20, 2021
    Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
    Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Statements
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis US Websites
  • Oncology HCP Resources
  • Gene Therapy Network
  • Medical Information
  • Sandoz
  • Global Site
Footer Bottom
© 2022 Novartis Pharmaceuticals Corporation
  • Terms of Use
  • Privacy Policy
  • Contacts
  • About Cookies
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for US Residents Only